Eupraxia Pharmac Stock Price, News & Analysis

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q3 2025 results and a business update on Nov 4, 2025. Key items: 52-week durable symptom and tissue responses observed after a single EP-104GI treatment (two-thirds of Cohort 5, N=3 remained in remission at 1 year).

The company closed an $80.5 million public offering (14,636,363 shares at $5.50) and held $89.0 million cash as of Sept 30, 2025, with a stated runway into the first half of 2028. Topline Phase 2b RESOLVE data expected by Q3 2026.

Operational notes: net loss of $6.4M for Q3 2025; management is monitoring potential impacts from proposed U.S.-Canada tariffs on supply chain and costs.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive clinical data from Cohort 9 of the RESOLVE trial for EP-104GI in Eosinophilic Esophagitis, testing the highest dose of 8mg per injection. The results showed significant improvements in tissue health outcomes and eosinophil reduction, with patients experiencing rapid clinical remission and maintaining long-term benefits.

Based on these promising results, the company plans to expand the Phase 2b portion of RESOLVE from 60 to at least 120 patients. The trial will use 8mg per injection with 20 injections per administration. Additionally, Eupraxia intends to broaden EP-104GI's development program by initiating trials for additional GI indications in H1 2026, including potential applications in fibrostenotic Crohn's, benign esophageal strictures, and Barrett's esophagus prevention.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has successfully closed its public offering of 14,636,363 common shares at US$5.50 per share, raising approximately US$80.5 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase additional shares.

The company plans to use the proceeds to advance its product pipeline, particularly the development of EP-104GI for eosinophilic esophagitis and its upcoming Phase 2b clinical readout. The funding is expected to extend the company's capital runway into the first quarter of 2028. Cantor and LifeSci Capital served as joint book-running managers, with Bloom Burton acting as co-manager for the offering.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced the pricing of its public offering of 12,727,273 common shares at US$5.50 per share, aiming to raise approximately US$70 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to an additional 1,909,090 shares under the same terms.

The offering, expected to close on September 24, 2025, is being managed by Cantor and LifeSci Capital as joint book-running managers, with Bloom Burton as co-manager. The proceeds will fund pipeline advancement, clinical trials, regulatory submissions, commercial preparation, and manufacturing scale-up activities. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced a proposed public offering of common shares. The company has filed a preliminary prospectus supplement to its base shelf prospectus for the offering, which includes a 30-day option for underwriters to purchase up to an additional 15% of shares.

The offering will be jointly managed by Cantor and LifeSci Capital as book-running managers, with Bloom Burton acting as co-manager. The proceeds will primarily fund the company's product pipeline development, including ongoing clinical trials, regulatory submissions, and commercial preparation. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.

The final terms and size of the offering will be determined at pricing, with completion subject to customary conditions including TSX and Nasdaq listing approvals.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced positive 1-year clinical results from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The trial demonstrated that 67% of patients in Cohort 5 (48mg dose) maintained clinical remission after 12 months.

Key findings include significant tissue health improvements, with patients treated with 4mg per injection showing 47% improvement in grade and 44% in stage at week 36. The drug maintained steady plasma levels through 52 weeks, below typical asthma inhaler levels. Importantly, no serious adverse events or oral/gastrointestinal candidiasis were reported.

The company believes EP-104GI could potentially offer a revolutionary once-yearly treatment option, administered during routine annual endoscopy procedures, presenting a significant advantage over current daily oral steroids or weekly biologics.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported Q2 2025 financial results and provided updates on its EP-104GI clinical program for Eosinophilic Esophagitis (EoE). The company has initiated the Phase 2b placebo-controlled portion of the RESOLVE trial, with topline data expected in H2 2026. The trial will enroll a minimum of 60 patients across 25 global sites.

Key financial metrics include a net loss of $8.7 million for Q2 2025, compared to $6.1 million in Q2 2024. Cash position stands at $19.8 million as of June 30, 2025, expected to fund operations into Q3 2026. Recent Phase 1b/2a data showed sustained positive treatment outcomes after nine months of therapy, with no serious adverse events reported.

Eupraxia Pharmaceuticals (NASDAQ:EPRX), a clinical-stage biotech company, has announced its participation in four upcoming investor conferences in August and September 2025. The company, which specializes in DiffuSphere™ technology for optimized local drug delivery, will present at the Canaccord Growth Conference (August 12-14), Citi Biopharma Conference (September 2-3), Cantor Global Healthcare Conference (September 3-5), and H.C. Wainwright Global Investment Conference (September 8-10).

The presentations will take place in Boston and New York, with scheduled times at 9:30am ET on August 13 at Canaccord and 9:10am ET on September 5 at Cantor.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) has initiated the Phase 2b placebo-controlled portion of its RESOLVE clinical trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The study will enroll minimum 60 patients across 25 global sites, evaluating two active doses against placebo over 12 months.

The trial's first active dose of 120 mg was selected based on encouraging early data from cohort 8, showing the largest decline in Peak Eosinophil Count and lowest EoEHSS scores at 4 weeks. The study will assess tissue health, symptom scores, and safety, with placebo patients eligible to receive EP-104GI after six months. Topline data is expected by Q3 2026, with additional Phase 2a data releases planned for September and November 2025.